SMAD2 and pulmonary fibrosis: Immunofluorescence and Western blot analyses confirmed these findings, underscoring TRPA1 inhibition's potential to mitigate M2 polarization and interfere with the TGF-β1-Smad2 pathway, offering a promising direction for pulmonary fibrosis treatment.